kff 2025 employer health benefits survey glp-1 coverage Family premiums for employer coverage

Who Might Consider BPC-157 and Who Should Avoid It Based on the preclinical data and clinical patterns of use, the patient populations most commonly prescribed BPC-157 for GI indications include: patients with persistent NSAID gastropathy despite PPI therapy, patients with functional GI symptoms attributed to intestinal barrier dysfunction, and patients with inflammatory bowel disease who have not responded adequately to biologic therapy and seek adjunctive options

optional extension to 12 weeks with periodic breaks

Clinics may provide complementary tools like body contouring lymphatic drainage and skin tightening

What if I wish I knew about these side effects before starting GLP-1 drugs

Allulose can be claimed as being FODMAP-friendly

Additionally, discrepancies in the chain of custody, where the samples handling and transfer are not adequately documented, can raise doubts about the reliability of the results